Anticoagulants - The Past, The Present, The Future - A Systematic Review
DOI:
https://doi.org/10.12775/JEHS.2024.68.49539Keywords
anticoagulant drugs, factor XI inhibitors, coagulationAbstract
Introduction: Anticoagulants have been discovered and developed over past 100 years. At the beginning unfractionated heparin found its applications, just later to fade into the background of newer and more effective drugs. Patients have been treated with more progressive medications – Low-Molecule-Weight Heparin (LMWH), Vitamin K Antagonists (VKA) and Novel Oral Anticoagulants (NOAC). As for today, deemed a turning point in anticoagulant therapy are inhibitors of factor XI. It is a ground-breaking innovation as it ensures high prevention of thrombotic episodes and guarantees intact physiological hemostasis.Current State of Knowledge: The coagulation cascade and molecules part taking in that have been discovered and described extensively and in detail. Unfractionated heparin is the oldest out of all and despite its simple action mechanism and adverse effects, is still a requested drug. Its lighter form, low-molecule-weight-heparin (LMWH) is an enhancement to the previous treatment due to its higher bioavailability and fewer side effects. Vitamin K antagonists (VKAs) are widely spread in medical environment thanks to their expanded mechanism of action, oral administration and reversibility of their overdose, as well as their well-developed anti-side effect therapy. Novel Oral Anticoagulants (NOACs) have been introduced to the market about 10 years ago. In spite of NOACs short period of clinical use, they were a huge change to the previous treating methods. Currently, the newest innovation in anticoagulant therapy are inhibitors of factor XI and its clinical trials outcome is promising for the future.Summary: The present article discusses history of anticoagulant drugs, their mechanism of action and usage but also focuses on the recent perspectives and developments as new anticoagulant drugs are being put to the test in therapeutic trials. The review underlines the importance of improvements in old therapeutic methods and exploring the new, more suitable ones.
References
Smith SA, Travers RJ, Morrissey JH. How it all starts: initiation of the clotting cascade. Crit Rev Biochem Mol Biol [Internet]. 2015 Jul 4 [cited 2024 Mar 17];50(4):326. Available from: /pmc/articles/PMC4826570/
Heestermans M, Poenou G, Hamzeh-Cognasse H, Cognasse F, Bertoletti L. Anticoagulants: A Short History, Their Mechanism of Action, Pharmacology, and Indications. Cells [Internet]. 2022 Oct 1 [cited 2024 Mar 13];11(20). Available from: /pmc/articles/PMC9600347/
Khan F, Tritschler T, Kahn SR, Rodger MA. Venous thromboembolism. Lancet [Internet]. 2021 Jul 3 [cited 2024 Mar 16];398(10294):64–77. Available from: https://pubmed.ncbi.nlm.nih.gov/33984268/
Risk Factors for Venous Thromboembolism | American Heart Association [Internet]. [cited 2024 Mar 16]. Available from: https://www.heart.org/en/health-topics/venous-thromboembolism/risk-factors-for-venous-thromboembolism-vte
Weitz JI, Harenberg J. New developments in anticoagulants: Past, present and future. Thromb Haemost [Internet]. 2017 [cited 2024 Mar 16];117(7):1283–8. Available from: http://www.thieme-connect.com/products/ejournals/html/10.1160/TH16-10-0807
Lutsey PL, Zakai NA. Epidemiology and prevention of venous thromboembolism. Nat Rev Cardiol [Internet]. 2023 Apr 1 [cited 2024 Mar 14];20(4):248. Available from: /pmc/articles/PMC9579604/
Renner E, Barnes GD. Antithrombotic Management of Venous Thromboembolism: JACC Focus Seminar. J Am Coll Cardiol [Internet]. 2020 Nov 3 [cited 2024 Mar 17];76(18):2142–54. Available from: https://www.jacc.org/doi/10.1016/j.jacc.2020.07.070
Palta S, Saroa R, Palta A. Overview of the coagulation system. Indian J Anaesth [Internet]. 2014 Sep 1 [cited 2024 Mar 16];58(5):515. Available from: /pmc/articles/PMC4260295/
Achneck HE, Sileshi B, Parikh A, Milano CA, Welsby IJ, Lawson JH. Pathophysiology of bleeding and clotting in the cardiac surgery patient: From vascular endothelium to circulatory assist device surface. Circulation [Internet]. 2010 Nov 16 [cited 2024 Mar 17];122(20):2068–77. Available from: https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.110.936773
Umerah C o., Momodu II. Anticoagulation. Cardiology Board Review, Second Edition [Internet]. 2023 Jul 17 [cited 2024 Mar 17];615–26. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560651/
Grover SP, Mackman N. Intrinsic Pathway of Coagulation and Thrombosis. Arterioscler Thromb Vasc Biol [Internet]. 2019 Mar 1 [cited 2024 Mar 17];39(3):331–8. Available from: https://www.ahajournals.org/doi/abs/10.1161/ATVBAHA.118.312130
Palta S, Saroa R, Palta A. Overview of the coagulation system. Indian J Anaesth [Internet]. 2014 Sep 1 [cited 2024 Mar 17];58(5):515. Available from: /pmc/articles/PMC4260295/
Weisel JW, Litvinov RI. Fibrin Formation, Structure and Properties. Subcell Biochem [Internet]. 2017 Jan 1 [cited 2024 Mar 18];82:405. Available from: /pmc/articles/PMC5536120/
Risman RA, Kirby NC, Bannish BE, Hudson NE, Tutwiler V. Fibrinolysis: an illustrated review. Res Pract Thromb Haemost [Internet]. 2023 Feb 1 [cited 2024 Mar 18];7(2):100081. Available from: /pmc/articles/PMC10024051/
Ashorobi D, Ameer MA, Fernandez R. Thrombosis. Cases in Laboratory Genetics and Genomics (LGG) Practice [Internet]. 2023 Aug 8 [cited 2024 Mar 16];125–8. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538430/
Franchini M, Liumbruno GM, Bonfanti C, Lippi G. The evolution of anticoagulant therapy. Blood Transfusion [Internet]. 2016 Mar 1 [cited 2024 Mar 14];14(2):175. Available from: /pmc/articles/PMC4781787/
Mannucci PM, Franchini M. Old and new anticoagulant drugs: A minireview. Ann Med [Internet]. 2011 Mar [cited 2024 Mar 14];43(2):116–23. Available from: https://www.tandfonline.com/action/journalInformation?journalCode=iann20
Mavrakanas T, Bounameaux H. The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism. Pharmacol Ther. 2011 Apr 1;130(1):46–58.
Bendz B, Sandset PM. Deep-vein thrombosis in long-haul flights. The Lancet. 2001 Sep;358(9284):837–8.
Schwarz T, Siegert G, Oettler W, Halbritter K, Beyer J, Frommhold R, et al. Venous Thrombosis After Long-haul Flights. Arch Intern Med [Internet]. 2003 Dec 8 [cited 2024 Mar 17];163(22):2759–64. Available from: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/757492
Watson HG, Baglin TP. Guidelines on travel-related venous thrombosis. [cited 2024 Mar 17]; Available from: https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2010.08408.x
Philbrick JT, Shumate R, Siadaty MS, Becker DM. Air Travel and Venous Thromboembolism: A Systematic Review. Medicine. 2007;22:107–14.
Ambra N, Mohammad OH, Naushad VA, Purayil NK, Mohamedali MG, Elzouki AN, et al. Venous Thromboembolism Among Hospitalized Patients: Incidence and Adequacy of Thromboprophylaxis – A Retrospective Study. Vasc Health Risk Manag [Internet]. 2022 [cited 2024 Mar 17];18:575. Available from: /pmc/articles/PMC9333096/
Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in Fatal Pulmonary Embolism and Venous Thrombosis by Perioperative Administration of Subcutaneous Heparin. http://dx.doi.org/101056/NEJM198805053181805 [Internet]. 2010 Jan 14 [cited 2024 Mar 16];318(18):1162–73. Available from: https://www.nejm.org/doi/10.1056/NEJM198805053181805
Encke A, Haas S, Kopp I. The Prophylaxis of Venous Thromboembolism. Dtsch Arztebl Int [Internet]. 2016 Aug 8 [cited 2024 Mar 14];113(31–32):532. Available from: /pmc/articles/PMC5012163/
Hirsh J, Anand SS, Halperin JL, Fuster V. Mechanism of Action and Pharmacology of Unfractionated Heparin. 2001 [cited 2024 Mar 16]; Available from: http://www.atvb.org
Wijesurendra RS, Casadei B. Mechanisms of atrial fibrillation. Heart [Internet]. 2019 Dec 1 [cited 2024 Mar 16];105(24):1860–7. Available from: https://pubmed.ncbi.nlm.nih.gov/31444267/
Yew Ding W, Protty MB, Davies IG, Lip GY. Relationship between lipoproteins, thrombosis, and atrial fibrillation. [cited 2024 Mar 16]; Available from: https://academic.oup.com/cardiovascres/article/118/3/716/6111888
Barra S, Providência R. Anticoagulation in atrial fibrillation. Heart [Internet]. 2021 Mar 1 [cited 2024 Mar 15];107(5):419–27. Available from: https://heart.bmj.com/content/107/5/419
Lip GYH, Banerjee ; Amitava, Boriani G, Chern En Chiang ;, Fargo R, Freedman B, et al. Antithrombotic Therapy for Atrial Fibrillation CHEST Guideline and Expert Panel Report. Chest [Internet]. 2018 [cited 2024 Mar 17];154:1121–201. Available from: https://doi.org/10.1016/j.chest.2018.07.040
Ezekowitz MD, Nagarakanti R, Noack H, Brueckmann M, Litherland C, Jacobs M, et al. Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease. Circulation. 2016 Aug 23;134(8):589–98.
Middeldorp S, Naue C, Köhler C. Thrombophilia, Thrombosis and Thromboprophylaxis in Pregnancy: For What and in Whom? Hamostaseologie [Internet]. 2022 [cited 2024 Mar 17];42:54–64. Available from: https://doi.org/
Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium Green-top Guideline No. 37a. 2015;
MiddletonP GJ. Cochrane Library Cochrane Database of Systematic Reviews Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period (Review). 2021 [cited 2024 Mar 17]; Available from: www.cochranelibrary.com
Montinari MR, Minelli S, De Caterina R. Eighty years of oral anticoagulation: Learning from history. Vascul Pharmacol. 2021 Dec 1;141:106918.
Montinari MR, Minelli S, De Caterina R. The first 3500 years of aspirin history from its roots-A concise summary. 2018 [cited 2024 Mar 15]; Available from: www.elsevier.com/locate/vph
Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. Br J Haematol. 2008 Jun;141(6):757–63.
Singh D. 100 Years of Heparin (1916-2016): Saga of Joys and Tears. Indian Journal of Vascular and Endovascular Surgery [Internet]. 2016 [cited 2024 Mar 15];3(4):128. Available from: https://journals.lww.com/ijvs/fulltext/2016/03040/100_years_of_heparin__1916_2016___saga_of_joys_and.4.aspx
Russo V, Imbalzano E, Heestermans M, Poenou G, Hamzeh-Cognasse H, Cognasse F, et al. Anticoagulants: A Short History, Their Mechanism of Action, Pharmacology, and Indications. 2022 [cited 2024 Mar 15]; Available from: https://doi.org/10.3390/cells11203214
Ramachandran S, Pitchai S. Story of warfarin: From rat poison to lifesaving drug. Indian Journal of Vascular and Endovascular Surgery [Internet]. 2018 [cited 2024 Mar 19];5(3):174. Available from: https://journals.lww.com/ijvs/fulltext/2018/05030/story_of_warfarin__from_rat_poison_to_lifesaving.10.aspx
Barrowcliffe TW. History of heparin. Handb Exp Pharmacol [Internet]. 2012 [cited 2024 Mar 15];207:3–22. Available from: https://link.springer.com/chapter/10.1007/978-3-642-23056-1_1
Anti-Xa assays: What is their role today in antithrombotic therapy? [cited 2024 Mar 16]; Available from: www.ccjm.org
Altiok E, Marx N. Oral anticoagulation—update on anticoagulation with vitamin K antagonists and non– vitamin K–dependent oral anticoagulants. Dtsch Arztebl Int . 2018;(115):776–83.
Ansell J. Is there a need for an alternative in the era of novel anticoagulants? Expert Rev Cardiovasc Ther [Internet]. 2015 Sep 2 [cited 2024 Mar 15];13(9):967–70. Available from: https://www.tandfonline.com/action/journalInformation?journalCode=ierk20
Yeh CH, Hogg K, Weitz JI. Overview of the new oral anticoagulants: opportunities and challenges. Arterioscler Thromb Vasc Biol [Internet]. 2015 May 27 [cited 2024 Mar 15];35(5):1056–65. Available from: https://pubmed.ncbi.nlm.nih.gov/25792448/
Wei S, Sawhney A, Khandait H, Meda A, Gupta V, Jain R. An update on applications and limitations of direct oral anticoagulants. Egypt J Intern Med. 2023 Apr 10;35(1).
Hirsh J, Anand SS, Halperin JL, Fuster V. Mechanism of Action and Pharmacology of Unfractionated Heparin. 2001 [cited 2024 Mar 18]; Available from: http://www.atvb.org
Dinis da Gama A. [The unknown history of heparin’s discovery]. Rev Port Cir Cardiotorac Vasc [Internet]. 2008 Jan 1 [cited 2024 Mar 18];15(1):25–30. Available from: https://europepmc.org/article/med/18618048
Derbalah A, Duffull S, Newall F, Moynihan K, Al-Sallami H. Revisiting the Pharmacology of Unfractionated Heparin. Clin Pharmacokinet [Internet]. 2019 Aug 1 [cited 2024 Mar 18];58(8):1015–28. Available from: https://link.springer.com/article/10.1007/s40262-019-00751-7
Abdel-Hafez A, Scott IA, Falconer N, Canaris S, Bonilla O, Marxen S, et al. Predicting Therapeutic Response to Unfractionated Heparin Therapy: Machine Learning Approach. Interact J Med Res [Internet]. 2022 Sep 19 [cited 2024 Mar 18];11(2):e34533. Available from: /pmc/articles/PMC9531006/
Watkins E, Thomas Ginat D, Small JE. Heparin. Neuroimaging Pharmacopoeia, Second Edition [Internet]. 2023 Jul 10 [cited 2024 Mar 19];313–6. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538247/
Nicolas D, Nicolas S, Hodgens A, Reed M. Heparin-Induced Thrombocytopenia. StatPearls [Internet]. 2023 May 16 [cited 2024 Mar 19]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK482330/
Arachchillage DRJ, Kamani F, Deplano S, Banya W, Laffan M. Should we abandon the APTT for monitoring unfractionated heparin? Thromb Res. 2017 Sep 1;157:157–61.
SHARMA S. LOW MOLECULAR WEIGHT HEPARINS. Med J Armed Forces India [Internet]. 1998 Jul [cited 2024 Mar 19];54(3):285. Available from: /pmc/articles/PMC5531654/
Akhtar F, Wan X, Wu G, Kesse S, Wang S, He S. Low-Molecular-Weight Heparins: Reduced Size Particulate Systems for Improved Therapeutic Outcomes. Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry [Internet]. 2018 [cited 2024 Mar 19];23(7). Available from: /pmc/articles/PMC6100363/
Harenberg J. Overview on guidelines and recommendations for generic low-molecular-weight heparins. Thromb Res [Internet]. 2011 Feb [cited 2024 Mar 19];127 Suppl 3(SUPPL. 3). Available from: https://pubmed.ncbi.nlm.nih.gov/21262425/
Solari F, Varacallo M. Low-Molecular-Weight Heparin (LMWH). StatPearls [Internet]. 2023 Aug 4 [cited 2024 Mar 19]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK525957/
Ibrahim SS, Osman R, Awad GAS, Mortada ND, Geneidy AS. Low molecular weight heparins for current and future uses: approaches for micro- and nano-particulate delivery. Drug Deliv [Internet]. 2016 Oct 12 [cited 2024 Mar 19];23(8):2661–7. Available from: https://www.tandfonline.com/doi/abs/10.3109/10717544.2015.1046570
Milling TJ, Ziebell CM. A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery R. Trends Cardiovasc Med [Internet]. 2020 [cited 2024 Mar 19];30:86–90. Available from: https://doi.org/10.1016/j.tcm.2019.03.004
Liu S, Shen G, Li W. Structural and cellular basis of vitamin K antagonism. 2022;
Barcellona D, Fenu L, Marongiu F. Point-of-care testing INR: An overview. Clin Chem Lab Med [Internet]. 2017 Jun 1 [cited 2024 Mar 19];55(6):800–5. Available from: https://www.degruyter.com/document/doi/10.1515/cclm-2016-0381/html
Dorgalaleh A, Favaloro EJ, Mehran Bahraini |, Rad | Fariba. Standardization of Prothrombin Time/International Normalized Ratio (PT/INR). Int J Lab Hematol [Internet]. 2021 [cited 2024 Mar 19];43:21–8. Available from: https://onlinelibrary.wiley.com/doi/10.1111/ijlh.13349
Salem JE, Sabouret P, Funck-Brentano C, Hulot JS. Pharmacology and mechanisms of action of new oral anticoagulants. [cited 2024 Mar 19]; Available from: https://onlinelibrary.wiley.com/doi/10.1111/fcp.12091
Lapostolle F, Siguret V, Martin AC, Pailleret C, Vigué B, Zerbib Y, et al. Vitamin K antagonists and emergencies. Eur J Emerg Med [Internet]. 2018 Dec 1 [cited 2024 Mar 19];25(6):378–86. Available from: https://pubmed.ncbi.nlm.nih.gov/29462053/
Van Gorp RH, Schurgers LJ. New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs). 2015 [cited 2024 Mar 19]; Available from: www.mdpi.com/journal/nutrients
Saviano A, Brigida M, Petruzziello C, Candelli M, Gabrielli M, Ojetti V. Gastrointestinal Bleeding Due to NOACs Use: Exploring the Molecular Mechanisms. 2022 [cited 2024 Mar 19]; Available from: https://doi.org/10.3390/ijms232213955
Wojtowicz D, Tomaszuk-Kazberuk A, Małyszko J, Koziński M. HEMATURIA AND OTHER KINDS OF BLEEDINGS ON NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION: AN UPDATED OVERVIEW ON OCCURRENCE, PATHOMECHANISMS AND MANAGEMENT. Wiad Lek. 2020;73(11):2528–34.
Ruff CT, Giugliano RP, Braunwald E, Hoff EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the effi cacy and safety of new oral anticoagulants with warfarin in patients with atrial fi brillation: a meta-analysis of randomised trials. www.thelancet.com [Internet]. 2014 [cited 2024 Mar 19];383. Available from: http://dx.doi.org/10.1016/
Malmström RE, Godman BB, Diogene E, Baumgärtel C, Bennie M, Bishop I, et al. Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Iñaki Gutiérrez-Ibarluzea [Internet]. [cited 2024 Mar 19];12. Available from: www.frontiersin.org
Singh Paresh Pai Harish Kumar Sheeba George Sandeep Mahapatra Vineet Garg N Gupta Kiran Makineni Gaurav Ganeshwala Pravin Narkhede Syed M H Naqvi Kumar Gaurav Mohammed Y K Hukkeri BG, Singh B, Pai P, Kumar H, George S, Mahapatra S, et al. Expert Recommendations on the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) from India: Current Perspective and Future Direction. 2022 [cited 2024 Mar 19];11:49–79. Available from: https://doi.org/10.1007/s40119-022-00254-w
Christopoulou EC, Filippatos TD, Elisaf MS. Non-hemorrhage-related adverse effects of rivaroxaban. Archives of Medical Science – Atherosclerotic Diseases. 2017 Dec 31;2(1):108–12.
Nopp S, Kraemmer D, Ay C. Factor XI Inhibitors for Prevention and Treatment of Venous Thromboembolism: A Review on the Rationale and Update on Current Evidence. Vol. 9, Frontiers in Cardiovascular Medicine. 2022.
Musiał J. Factor XI inhibitors — a breakthrough in prevention and treatment of thromboembolic disorders. Journal of Transfusion Medicine. 2022;15(4).
Perera V, Abelian G, Li D, Wang Z, Zhang L, Lubin S, et al. Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants. Clin Pharmacokinet. 2022;61(6).
Weitz JI, Strony J, Ageno W, Gailani D, Hylek EM, Lassen MR, et al. Milvexian for the Prevention of Venous Thromboembolism. New England Journal of Medicine. 2021;385(23).
Büller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, et al. Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis. New England Journal of Medicine. 2015;372(3).
Weitz JI, Bauersachs R, Becker B, Berkowitz SD, Freitas MCS, Lassen MR, et al. Effect of Osocimab in Preventing Venous Thromboembolism among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. JAMA - Journal of the American Medical Association. 2020;323(2).
Muscente F, De Caterina R. The new in anticoagulation: factor XI inhibitors. European Heart Journal Supplements. 2023;25(Supplement_B).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Klaudia Warzycka, Karolina Maliszewska, Kinga Woźniak, Monika Gardian-Baj, Magdalena Jung, Patryk Hedesz, Maximilian Jung, Aleksandra Doryń, Krystian Jędral, Aleksandra Włodarczyk, Alicja Szczerbiak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 417
Number of citations: 0
